Olaposi Idowu Omotuyi
Research Subjects
Research Interests
Olaposi Idowu Omotuyi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Babatunde Oluwaseun Ibitoye
Ekiti State University
1 shared publicationEhisdiame Favour Okoh
Adekunle Ajasin University
1 shared publication- Emmanuel Sunday Omirin
Cell and Molecular Biology Unit, Eureka Research Laboratory, Babcock University, Ilishan-Remo, Nigeria
1 shared publication - Ezekiel Abiola Olugbogi
Babcock University
1 shared publication Michael Aladejare Aderiye
Ekiti State University
1 shared publicationOlabode Oluwagbemiga Adelegan
Ekiti State University
1 shared publication
Latest Publications
- Open Access
Molecular Dynamics Simulations on Quercetin-3-(6-Malonylglucoside) From Morus Alba Shows Optimal Inhibition of Bcl-2 with Favorable Anti-Tumor Activities
The target of most cancer chemotherapeutic agents is to drive cancer cells toward death. A fine balance between anti-apoptotic and pro-apoptotic proteins is needed to maintain cellular homeostasis. Any shift favoring the pro-apoptotic ones is needed to drive cellular death in cancer chemotherapy. However, anti-apoptotic proteins such as Bcl-2 and Bcl-xL bind with pro-apoptotic proteins to hinder apoptosis mechanisms. Overexpression of these anti-apoptotic proteins lead to several cancers by preventing apoptosis. In this study, molecular docking, ADMET predictions, and molecular dynamics simulations were performed for the identification of potent inhibitors of anti-apoptotic Bcl-2 with compounds of Morus alba. Our study discovered that Quercetin-3-(6-Malonylglucoside) and Epigallocatechin gallate recorded excellent binding affinity with Bcl-2. Therefore, we conclude that compounds of Morus alba should be subjected to further experimental studies ( in vitro and in vivo) in order to confirm the findings that they could be used as better options in cancer chemotherapy.
Open AccessMolecular Dynamics Simulations on Quercetin-3-(6-Malonylglucoside) From Morus Alba Shows Optimal Inhibition of Bcl-2 with Favorable Anti-Tumor Activities
The target of most cancer chemotherapeutic agents is to drive cancer cells toward death. A fine balance between anti-apoptotic and pro-apoptotic proteins is needed to maintain cellular homeostasis. Any shift favoring the pro-apoptotic ones is needed to drive cellular death in cancer chemotherapy. However, anti-apoptotic proteins such as Bcl-2 and Bcl-xL bind with pro-apoptotic proteins to hinder apoptosis mechanisms. Overexpression of these anti-apoptotic proteins lead to several cancers by preventing apoptosis. In this study, molecular docking, ADMET predictions, and molecular dynamics simulations were performed for the identification of potent inhibitors of anti-apoptotic Bcl-2 with compounds of Morus alba. Our study discovered that Quercetin-3-(6-Malonylglucoside) and Epigallocatechin gallate recorded excellent binding affinity with Bcl-2. Therefore, we conclude that compounds of Morus alba should be subjected to further experimental studies ( in vitro and in vivo) in order to confirm the findings that they could be used as better options in cancer chemotherapy.